Ayala Pharmaceuticals
Ayala Pharmaceuticals is a clinical-stage oncology company that previously focused on developing small molecule therapeutics for rare and aggressive cancers. In the first quarter of 2024, the company sold its primary drug candidates, AL102 and AL101, to Immunome, Inc. The company currently manages legacy assets such as BST-236 and handles ongoing regulatory and SEC reporting requirements.
Biotechnology
Healthcare
Oncology
Funding summary
- Total raised
- €26.7M
- Funding rounds
- 1
Investors in Ayala Pharmaceuticals
Investors on record for Ayala Pharmaceuticals. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Ayala Pharmaceuticals?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors